Oncology Institute (TOI) said Monday it has received certification to start administering the Pluvicto radiopharmaceutical in its outpatient radiation oncology practices in California.
Pluvicto, which is used to treat some types of metastatic prostate cancer, has mainly been administered in hospital settings before, the company said.
Oncology Institute shares were more than 7% higher in recent trading
Price: 0.28, Change: +0.02, Percent Change: +7.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.